A phase 2 study of HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy as firstline therapy in advanced or recurrent squamous non-small cell lung cancer

Safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of HLX301, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors